MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells
Cells · 06.06.2026 · 15 (12) · 1043
DOI: 10.3390/cells15121043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 06.06.2026. Verfasst von Brigitta Ignoto und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy. Hauptthemen laut MEDLINE: Gefitinib, MicroRNAs, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Ministry of Health.
Abstract (Originalsprache)
Mechanisms of primary and acquired resistance are responsible for treatment failure with the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors (EGFR-TKIs) in the majority of patients with advanced Non-Small-Cell Lung Cancer (NSCLC) carrying EGFR-activating mutations. MicroRNAs (miRNAs) are important modulators of EGFR signaling in lung cancer. Recent studies suggested the role of miR-23c as a tumor suppressor or oncogenic miRNA in different tumor types. However, the role of miR-23c in NSCLC carrying EGFR mutations and its involvement in resistance to EGFR-TKIs has not been explored yet. We found that miR-23c was strongly downregulated in H1975 and HCC827-Gefitinib-Resistant (GR) NSCLC cell lines with intrinsic and acquired resistance to gefitinib, respectively, as compared to gefitinib-sensitive cell lines. Moreover, we demonstrated that miR-23c mimic inhibited proliferation, migration, invasion, and epithelial–mesenchymal transition of resistant cells and that Interleukin-6 Receptor (IL-6R) is a direct target of miR-23c in H1975 and HCC827-GR cell lines. Importantly, miR-23c mimic re-sensitized NSCLC-resistant cells to gefitinib, whereas the combination of miR-23c mimic with a neutralizing IL-6R antibody potentiated the sensitivity to the drug. Collectively, our data demonstrated that miR-23c acts as a tumor suppressor in NSCLC cell lines carrying EGFR mutations and that the axis miR-23c/IL-6R might represent a potential target for the development of therapeutic approaches to overcome resistance to gefitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Naples, Italy.
- Center for Advanced Molecular Diagnostics in Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
- Thoracic Department, Istituto Nazionale Tumori-RCCS-Fondazione G. Pascale, 80131 Naples, Italy.
ORCID-Profile: Brigitta Ignoto, Ilaria Assunta Parisi, Cristin Roma, Rosa Camerlingo, Monica Rosaria Maiello, Nicola Normanno, Alessandro Morabito
Förderung
- Ministero della Salute
- Ministry of Health
Zitieren
APA
Ignoto, B., Parisi, I. A., Roma, C., Camerlingo, R., Dotolo, S., Tufano, S., Maiello, M. R., Normanno, N., Morabito, A., De Luca, A., & Frezzetti, D. (2026). MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. Cells, 15(12), 1043. https://doi.org/10.3390/cells15121043
Vancouver
Ignoto B, Parisi IA, Roma C, Camerlingo R, Dotolo S, Tufano S, et al. MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. Cells. 2026;15(12):1043. doi:10.3390/cells15121043
BibTeX
@article{Ignoto2026,
author = {Ignoto, Brigitta and Parisi, Ilaria Assunta and Roma, Cristin and Camerlingo, Rosa and Dotolo, Serena and Tufano, Salvatore and Maiello, Monica Rosaria and Normanno, Nicola and Morabito, Alessandro and De Luca, Antonella and Frezzetti, Daniela},
title = {MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells},
journal = {Cells},
year = {2026},
volume = {15},
number = {12},
pages = {1043},
doi = {10.3390/cells15121043}
}
EUVIMED